Register for an account


Enter your name and email address below.

Your email address is used to log in and will not be shared or sold. Read our privacy policy.


Website access code

Enter your access code into the form field below.

If you are a Zinio, Nook, Kindle, Apple, or Google Play subscriber, you can enter your website access code to gain subscriber access. Your website access code is located in the upper right corner of the Table of Contents page of your digital edition.


Drug Couriers for Brain Injuries

A small protein could lead to a cure for traumatic brain injuries.

By Teal BurrellDecember 21, 2016 6:00 AM
In a mouse brain, the CAQK peptide binds to injured sites more effectively than the control. Cooler colors signal lower peptide levels; warmer colors signal higher levels. (Credit: Mann et al. 2016 Nature Communication. Reprinted by permission from MacMillan Publishers Ltd.)


Sign up for our email newsletter for the latest science news

A short protein fragment, or peptide, may lead the way to healing traumatic brain injuries, a primary cause of death and disability among youth.

Currently, drugs to treat such injuries are injected directly into the brain — an invasive technique — or into the bloodstream, which allows the medication to spread throughout the brain, causing harmful side effects. Attaching drugs to the new peptide, called CAQK, would avoid these problems. The peptide, just four amino acids long, binds to a protein complex that’s more abundant in injured areas and can therefore carry the therapy through the blood straight to the damaged sites.

The 1-in-a-billion CAQK peptide (dark blue) also targets injured sites in human brain samples, showing its potential for precise drug delivery. (Credit: Mann et al. 2016 Nature Communications. Reprinted by permission from MacMillan Publishers Ltd)

To find the chemical courier, a team led by Erkki Ruoslahti of Sanford Burnham Prebys Medical Discovery Institute in California tested 1 billion random combinations of amino acids — just one robustly bound specifically to injured brain tissue of mice and humans. The results were published in Nature Communications in June.

“We get more of the drug to go to the injury and to stay there,” Ruoslahti says. Now, older treatments that were abandoned because they didn’t latch to injured areas or had negative side effects could be revived.

3 Free Articles Left

Want it all? Get unlimited access when you subscribe.


Already a subscriber? Register or Log In

Want unlimited access?

Subscribe today and save 70%


Already a subscriber? Register or Log In